Don’t Overlook This Cancer Biotech In The Age Of Coronavirus
This clinical-stage biopharmaceutical company focused on developing treatments for different kinds of cancers just recently launched an IPO, making it just the second IPO to…
Biotech Stocks
3 Biotech Stocks Trading Under $2 With “Serious Upside Potential”
While the COVID-19 pandemic is far from over, there have been some small glimmers of hope in recent days – and the market responded accordingly.…
2 Top Picks From “The Rest Of The Biopharma Industry”
While most of the attention in the biotech space is currently focused on companies working on potential vaccines for the novel coronavirus and treatments for…
As The COVID-19 Vaccine Competition Heats Up, Consider These Biotech Stocks & ETFs
As the number of those infected with COVID-19 goes up domestically and globally, the competition to develop a vaccine is heating up – and the…
Life-Saving Biotechs Offering “Life-Changing Gains”
No matter what happens to the economy, people aren’t going to stop taking their prescription medications. As a result, the author of today’s article suggests…
2 Biotechs For Exposure To “Unique, Cutting-Edge” Approaches To Treating Alzheimer’s Disease
It has been over 15 years since any new drug for the treatment of Alzheimer’s has been approved – but a pair of relatively new…
A Promising Biotech IPO – And Its Potential Problems
Gossamer Bio is a San Diego-based biotech that is readying for an initial public offering – and with a diverse pipeline including potential treatments for…
5 Stocks With Small Price Tags And Big Upside Potential
Low-priced stocks offer investors – especially more aggressive traders – the opportunity to not only make a decent profit in the event of even relatively…
These Beaten-Down Biotechs’ Pipelines Are Available For Practically Free
“You don’t usually get the chance to pick up the entire research-and-development arm of a major company for free,” acknowledges the author of today’s article…
3 Biotech Stocks With Powerful Catalysts – Including A Potential Acquisition Target
The biotech sector outperformed the S&P 500 last year – and further strong performance could lie ahead thanks in part to the tax break for…